Migraine with aura versus migraine without aura: Pain intensity and associated symptom intensities after placebo

被引:8
作者
Bigal, ME
Bordini, CA
Sheftell, FD
Speciali, JG
Bigal, JOM
机构
[1] New England Ctr Headaches, Stamford, CT 06903 USA
[2] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[3] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Neurol, BR-05508 Sao Paulo, Brazil
[4] Univ Riberirao Preto, Ribeirao Preto, SP, Brazil
来源
HEADACHE | 2002年 / 42卷 / 09期
关键词
migraine with aura; migraine without aura; placebo; stratification;
D O I
10.1046/j.1526-4610.2002.02205.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the intensity of pain and associated symptoms after placebo administration in patients with migraine with aura and migraine without aura. Background.-Studies that evaluate drugs used in the acute treatment of migraine ideally should include a placebo arm. The International Headache Society also recommends stratification according to age and sex but not by the presence versus absence of aura. Methods.-The study was conducted as part of a placebo controlled randomized survey comparing four active drugs against placebo in the acute treatment of migraine. Patients were blinded as to treatment received. Placebo consisted of 10 mL of normal saline (0.9%) intravenously. Pain intensity was evaluated by a 10-point analogical-verbal scale. Nausea, photophobia, and phonophobia were evaluated by a four-point analogical-verbal scale. For statistical analysis, unpaired t-test with Welch correction was used. Results.-After placebo administration, reduction of symptom intensity (pain, nausea, photophobia, and phonophobia) in patients with migraine without aura was significantly greater than that observed in patients with migraine with aura. Conclusions.-Our findings suggest that studies comparing placebo against an active drug should use stratification according to the presence versus absence of aura.
引用
收藏
页码:872 / 877
页数:6
相关论文
共 17 条
[1]  
ALTMANN DG, 1991, PRACTICAL STAT MED R, P84
[2]  
[Anonymous], 1991, Cephalalgia, V11, P1
[3]  
BIGAL ME, 2002, ARQ NEURO-PSIQUIAT, P60
[4]  
Bussone G, 1999, CEPHALALGIA, V19, P232
[5]   SUMATRIPTAN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN THE ACUTE TREATMENT OF MIGRAINE AND CLUSTER HEADACHE [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1992, 43 (05) :776-798
[6]   The randomized controlled trial gets a middle-aged checkup [J].
Jadad, AR ;
Rennie, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (04) :319-320
[7]   Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - Three double-blind, randomized, placebo-controlled trials [J].
Lipton, RB ;
Stewart, WF ;
Ryan, RE ;
Saper, J ;
Silberstein, S ;
Sheftell, F .
ARCHIVES OF NEUROLOGY, 1998, 55 (02) :210-217
[8]   REPORTING STANDARDS AND RESEARCH STRATEGIES FOR CONTROLLED TRIALS - AGENDA FOR THE EDITOR [J].
MOSTELLER, F ;
GILBERT, JP ;
MCPEEK, B .
CONTROLLED CLINICAL TRIALS, 1980, 1 (01) :37-58
[9]   METHODOLOGY OF CLINICAL-TRIALS OF SUMATRIPTAN IN MIGRAINE AND CLUSTER HEADACHE [J].
PILGRIM, AJ .
EUROPEAN NEUROLOGY, 1991, 31 (05) :295-299
[10]   BIAS IN ANALYTIC RESEARCH [J].
SACKETT, DL .
JOURNAL OF CHRONIC DISEASES, 1979, 32 (1-2) :51-63